Introduction
In this article, we describe a novel antibody-drug conjugate (ADC; SGN-LIV1A), targeting the zinc transporter LIV-1 (SLC39A6) for the treatment of metastatic breast cancer. LIV-1 was previously known to be expressed by estrogen receptor-positive breast cancers...
Description of Liv-1 Targeting Antibody Drug Conjugate
In this article, a novel antibody-drug conjugate (ADC; SGN-LIV1A) targeting the zinc transporter LIV-1 (SLC39A6) for metastatic breast cancer treatment is discussed. LIV-1, a transmembrane protein expressed in various cancer types, is the focus of this ADC. The investigational ADC, SGN-LIV1A, comprises a humanized IgG1 antibody linked to monomethyl auristatin E (MMAE). This ADC is designed to target LIV-1 on cell surfaces, inducing potent cytotoxic cell killing. The promising potential of SGN-LIV1A as a therapeutic agent for LIV-1-expressing cancers is highlighted…
Background Information
Liv-1, a zinc transporter expressed in various cancers, is targeted by the investigational ADC SGN-LIV1A. This ADC comprises a humanized IgG1 antibody linked to MMAE for potent cell killing.
Liv-1 Protein and Its Role in Breast Cancer
Liv-1, a zinc transporter, is highly prevalent in breast cancer cells. The investigational ADC SGN-LIV1A targets Liv-1 using a humanized IgG1 monoclonal antibody conjugated to monomethyl auristatin E (MMAE). Liv-1 is expressed in various cancer types and plays a critical role in metastatic progression. The expression of Liv-1 is maintained after hormonal therapy, making it a promising target for ADC therapy in breast cancer patients.
Ladiratuzumab Vedotin (LV) as an Investigational ADC
Ladiratuzumab vedotin (LV), also known as SGN-LIV1A, is an investigational antibody-drug conjugate (ADC) developed to target the zinc transporter LIV-1 (SLC39A6) in various cancer types. This novel ADC combines a humanized IgG1 monoclonal antibody with monomethyl auristatin E (MMAE) via a protease-cleavable linker. When LV binds to LIV-1 on cell surfaces, it triggers internalization and the release of MMAE, leading to potent cytotoxic cell killing. LV shows promising potential as a targeted therapy for cancers expressing LIV-1.
Clinical Trials and Development
The Phase I clinical trial of BRY812, a novel antibody-drug conjugate (ADC) that targets LIV-1, has been initiated for advanced malignant tumors. This third-generation ADC shows promise as a targeted therapy for treating various cancer types.
Phase I Clinical Trial of BRY812 for Advanced Malignant Tumors
BioRay Pharmaceutical Co., Ltd. has initiated a Phase I clinical trial for BRY812, a third-generation antibody-drug conjugate (ADC) targeting LIV-1 for advanced malignant tumors. The trial, conducted at Sun Yat-sen Memorial Hospital, marks a significant advancement in targeted cancer therapy.
Acceptance of BRY812 by China NMPA for Clinical Trial
BRY812, a novel antibody-drug conjugate (ADC) targeting LIV-1, has been accepted by the China National Medical Products Administration (NMPA) for a clinical trial. This acceptance marks a significant step in the development of targeted therapies against advanced malignant tumors.
Advancements and Future Prospects
The development of Liv-1 targeting antibody-drug conjugates (ADCs) like SGN-LIV1A presents exciting prospects for the treatment of metastatic breast cancer. Engineering technologies continue to enhance ADC optimization٫ offering novel targets and innovative strategies to improve efficacy in solid tumors.
Role of Liv-1 as a Promising Target for ADCs
Liv-1, a zinc transporter, serves as a promising target for antibody-drug conjugates (ADCs) in cancer therapy. The expression of Liv-1 in various cancer types, including triple-negative breast cancer, highlights its potential as a therapeutic target. ADCs like SGN-LIV1A, specifically designed to target Liv-1, offer a targeted approach for cancer treatment with reduced systemic toxicity and potent antitumor effects.
Engineering Technologies and Novel Targets for ADC Optimization
Constant advancements in engineering technologies are enhancing the optimization of antibody-drug conjugates (ADCs) targeting Liv-1. These technologies aim to improve the efficacy of ADCs by introducing novel targets and innovative strategies for optimal drug delivery and cytotoxic effects in solid tumors. The evolution of engineering techniques is crucial for refining the precision and therapeutic potential of ADCs in cancer treatment.
Leave a Reply